These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 23462751)
1. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Ahn SJ; Woo SJ; Kim KE; Park KH Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2115-22. PubMed ID: 23462751 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Yang HS; Kim JG; Kim JT; Joe SG Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429 [TBL] [Abstract][Full Text] [Related]
3. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization. Ahn SJ; Park KH; Woo SJ Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553 [TBL] [Abstract][Full Text] [Related]
5. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Kim H; Lee K; Lee CS; Byeon SH; Lee SC Retina; 2015 Mar; 35(3):481-6. PubMed ID: 25313710 [TBL] [Abstract][Full Text] [Related]
6. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography. You JY; Chung H; Kim HC Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011 [TBL] [Abstract][Full Text] [Related]
8. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050 [TBL] [Abstract][Full Text] [Related]
9. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization. Cao XS; Peng XY; You QS; Zhang YP; Jonas JB Retina; 2014 Aug; 34(8):1554-9. PubMed ID: 24667570 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926 [TBL] [Abstract][Full Text] [Related]
17. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519 [TBL] [Abstract][Full Text] [Related]
18. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991 [TBL] [Abstract][Full Text] [Related]
19. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072 [TBL] [Abstract][Full Text] [Related]
20. Subfoveal choroidal thickness in idiopathic choroidal neovascularization. Ahn SJ; Kim TW; Ahn J; Woo SJ; Park KH; Lee BR Ophthalmology; 2014 Jul; 121(7):1486-7.e2. PubMed ID: 24793527 [No Abstract] [Full Text] [Related] [Next] [New Search]